Vaxart, Inc.
NASDAQ:VXRTBiotechnology
-$0.01 today
- Market cap
- $129.30M
- Beta
- 1.09
- P/E (TTM)
- 3.6
- EPS (TTM)
- $0.15
Volume 0.12M
Average 0.41M
VXRT Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Vaxart, Inc.NASDAQ: VXRT
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $1.48M fell 39.7% year over year, behind the -25.5% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 13.6% from the prior quarter. Over 3 fiscal years it compounded at -15.1% a year.
Context
- Stock-based compensation amounted to 3.5% of revenue in FY2025, down 36.6 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -39.7% toward the trailing-twelve-month pace of -25.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 8.31M USD
- Year-over-year change
- -27.7%
- 4-year CAGR
- -1.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.31M | -27.7% |
| FY2024 | 2024-12-31 | 11.5M | -18.6% |
| FY2023 | 2023-12-31 | 14.13M | +4.0% |
| FY2022 | 2022-12-31 | 13.59M | +53.2% |
| FY2021 | 2021-12-31 | 8.87M | — |
Stock-Based Compensation vs competitors
How VXRT compares with its peers on the latest reported figures
- VXRT's LTM Mar 2026 stock-based compensation of $7.34M is the 6th largest of the 10 companies compared; the peer median is $10.76M.
- Its year-over-year change of -25.5% is the 7th highest of 10, against a peer median of -12.1%.
- Stock-based compensation amounts to 2.9% of revenue for VXRT, versus a peer median of 117.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $22.45M | -34.1% | +7.7% | 33.9% | |
| LTM Mar 2026 | $13.93M | -47.2% | -30.3% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $13.11M | -11.0% | +88.9% | — |
| LTM Mar 2026 | $11.29M | +44.4% | +3.8% | — | |
| LTM Mar 2026 | $10.76M | -2.0% | +37.0% | 117.7% | |
| LTM Mar 2026 | $7.34M | -25.5% | -15.1% | 2.9% | |
CBUSCibus, Inc. | LTM Mar 2026 | $7.26M | -32.3% | +27.0% | 169.4% |
| LTM Mar 2026 | $5.81M | -25.3% | -16.6% | — | |
| LTM Mar 2026 | $4.61M | +14.2% | — | 117.2% | |
| LTM Mar 2026 | $2.1M | -12.1% | +36.1% | — | |
| Peer median (excluding VXRT) | $10.76M | -12.1% | +17.4% | 117.5% | |
Competitors are the stored peer set for VXRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (70.47M) | (107.76M) | (82.47M) | (66.95M) | 16.33M |
| Depreciation & Amortization | 4.21M | 5.81M | 8.62M | 8.85M | 8.58M |
| Deferred Income Tax | 3.09M | 4.09M | 0 | 0 | 0 |
| Stock-Based Compensation | 8.87M | 13.59M | 14.13M | 11.5M | 8.31M |
| Change in Working Capital | (2.12M) | (4.7M) | (10.85M) | 3.26M | (22.56M) |
| Accounts Receivables | 263K | 51K | (2.99M) | (2.75M) | (39.38M) |
| Inventory | 0 | (7.11M) | 0 | 0 | 0 |
| Accounts Payables | 1.63M | 357K | (2.44M) | 5.27M | 14.64M |
| Other Working Capital | (4.01M) | 2M | (5.42M) | 742K | 2.17M |
| Other Non-Cash Items | (3.41M) | (5.81M) | 106K | (1.43M) | (2.94M) |
| Operating Cash Flow | (59.83M) | (94.78M) | (70.45M) | (44.76M) | 7.71M |
| Capital Expenditures | (5.16M) | (9.6M) | (1.87M) | (554K) | (145K) |
| Acquisitions (Net) | (4.83M) | 10.81M | 120K | 0 | 0 |
| Purchases of Investments | (44.81M) | (55.01M) | (27.5M) | (54.33M) | (19.03M) |
| Sales of Investments | 5.7M | 44.2M | 73.2M | 43.5M | 40M |
| Other Investing Activities | 0 | (10.81M) | 0 | (9.95M) | (4.2M) |
| Investing Cash Flow | (49.1M) | (20.42M) | 43.95M | (21.32M) | 16.63M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 122.21M | 17.24M | 15.03M | 56.78M | 4.44M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.59M | 225K | 213K | (214K) | (199K) |
| Financing Cash Flow | 125.8M | 17.46M | 15.24M | 56.56M | 4.24M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 16.88M | (97.73M) | (11.26M) | (9.53M) | 28.59M |
| Free Cash Flow | (64.99M) | (104.38M) | (72.32M) | (45.32M) | 7.57M |
Vaxart, Inc.
NASDAQ:VXRT
Intrinsic Alpha fair value
Locked
Current Price
$0.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.